Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Moderna (0QF) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Mrna-1010, Fluarix Trivalent, Seasonal Influenza VaccineSeasonal InfluenzaPhase IRecruitingA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenOct 06, 2026
Mrna-1273, Mrna-1283Sars-Cov-2Phase IIRecruitingA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeSep 02, 2026―
Mrna-1345, Mrna-1365Respiratory Syncytial Virus (Rsv), Human Metapneuomovirus (Hmpv)Phase IRecruitingA Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsAug 10, 2026
Mrna-1469Ebola-Bundibugyo Virus Disease (Ebola-Bdbv)Phase IActive Not RecruitingA Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsJul 27, 2026
Mrna-1982Lyme DiseasePhase IIActive Not RecruitingA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)Apr 24, 2026
Intismeran, Pembrolizumab Coformulated With Berahyaluronidase Alfa, Mrna-4157, V940Non-small Cell Lung CancerPhase IIIRecruitingA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)Apr 01, 2026
Mrna-1018-H5InfluenzaPhase IIIActive Not RecruitingA Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsMar 22, 2026
Mrna-1273, Mrna-1283, Mrna-1283.222, Mrna-1273.222, Mrna-1283.815, Mrna-1273.815, Mrna-1283.211, Mrna-1283.529, Mrna-1283.251 Variant-Containing FormulationSars-Cov-2Phase IVRecruitingA Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Nov 25, 2025
Carboplatin, Pembrolizumab, Paclitaxel, Nab-Paclitaxel, Intismeran Autogene, V940, Keytruda, Mrna-4157Squamous Non-Small Cell Lung CancerPhase IIRecruitingA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Oct 24, 2025
Mrna-2808Relapsed Or Refractory Multiple Myelomaphase1AndPhase2RecruitingA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaAug 07, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Moderna (CH:0QF) have in its pipeline
Moderna CH:0QF is currently developing the following drugs: Mrna-1010, Fluarix Trivalent, Seasonal Influenza Vaccine, Mrna-1273, Mrna-1283, Mrna-1345, Mrna-1365, Mrna-1469, Mrna-1982, Intismeran, Pembrolizumab Coformulated With Berahyaluronidase Alfa, Mrna-4157, V940, Mrna-1018-H5, Mrna-1273, Mrna-1283, Mrna-1283.222, Mrna-1273.222, Mrna-1283.815, Mrna-1273.815, Mrna-1283.211, Mrna-1283.529, Mrna-1283.251 Variant-Containing Formulation, Carboplatin, Pembrolizumab, Paclitaxel, Nab-Paclitaxel, Intismeran Autogene, V940, Keytruda, Mrna-4157, Mrna-2808, Mrna-1345, Mrna-4106, Nivolumab/Relatlimab, Influenza Vaccine, Covid-19 Vaccine, Investigational Influenza Vaccine, Mrna-1083 Composition 1 Dose A Lot A, Mrna-1083 Composition 1 Dose A Lot B, Mrna-1083 Composition 1 Dose B, Mrna-1083 Composition 1 Dose C, Mrna-1083 Composition 2 Dose A, Mrna-1083 Composition 2 Dose B, Mrna-1083 Composition 3 Dose A, Mrna-1083 Composition 3 Dose B, Investigational Covid-19 Vaccine Lot A, Investigational Covid-19 Vaccine Lot B, Bcg, Intismeran Autogene, Mrna-4157, Mrna-1195, Fluarix Tetra, Mrna-1273, Mrna-1083, Licensed Influenza Vaccine, Sars-Cov-2 Vaccine, Mrna-0184, Mrna-1273.712, Fluarix, Fluarix Tetra, Influsplit Tetra, Mrna-1010, Alpharix Tetra, Mrna-1403, Carboplatin, Gemcitabine, Cisplatin, Pembrolizumab, Paclitaxel, Pemetrexed, Intismeran Autogene, Keytruda, Mrna-4157, Mrna-1273 Variant-Containing Formulation, Mrna-1083, Investigational Mrna-1273.815, Licensed Spikevax Vaccine, Pembrolizumab, Surgery, Intismeran Autogene, Keytruda, Mrna-4157, V940, Mrna-3210, Mrna-1647, Influenza Vaccine, Covid-19 Vaccine, Mrna-1083, Pembrolizumab, Intismeran Autogene, Keytruda, Mrna-4157, Fluzone Hd, Mrna-1345, Bexsero, Mrna-1608, Mrna-1769, Mrna-1403, Mrna-1405, Mrna-1975, Mrna-1982, Mrna-1018 For H5n8, Mrna-1018 For H7n9, Mrna-1018 For H5 Only, Mrna-1018 For H7 Only, Mrna-1018 For H5 Only-Cg, Mrna-2736. These drug candidates are in various stages of clinical development as the company works toward FDA approval.